Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa

被引：28

作者：

Ocheretyaner, Eric R. ^{[1
,2
]}

Park, Tae Eun ^{[3
]}

机构：

[1] LIU Pharm Arnold & Marie Schwartz Coll Pharm & Hl, Div Pharm Practice, Brooklyn, NY USA

[2] Kings Cty Hosp Ctr, Dept Pharm, Brooklyn, NY USA

[3] BronxCare Hlth Syst, Dept Pharm, Bronx, NY USA

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2018年 / 16卷 / 07期

关键词：

Delafloxacin; Pseudomonas aeruginosa; methicillin-resistant Staphylococcus aureus; MRSA; fluoroquinolone; SKIN-STRUCTURE INFECTIONS; IN-VITRO ACTIVITY; ACUTE BACTERIAL SKIN; ACUTE KIDNEY INJURY; STREPTOCOCCUS-PNEUMONIAE; ANTIBACTERIAL ACTIVITIES; NEISSERIA-GONORRHOEAE; HEALTHY-VOLUNTEERS; DOUBLE-BLIND; VANCOMYCIN;

D O I：

10.1080/14787210.2018.1489721

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: The resistance to current antimicrobial agents, including fluoroquinolones, has continued to grow among various pathogens indicating a need for new antimicrobials to combat multi-drug resistant (MDR) organisms. In June 2017, delafloxacin received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) in adults caused by designated susceptible bacteria.Areas covered: This review describes the pharmacology, pharmacodynamics, pharmacokinetics, product information, efficacy, and safety of delafloxacin.Expert commentary: Delafloxacin is a novel oral and intravenous fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, offering a new option for the treatment of ABSSSI and potentially for complicated urinary tract infections and severe community-acquired bacterial pneumonia.

引用

页码：523 / 530

页数：8

共 39 条

[1] In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates [J].

Adam, Heather J. ;

Laing, Nancy M. ;

King, C. Richard ;

Lulashnyk, Ben ;

Hoban, Daryl J. ;

Zhanel, George G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) :4915-4920

[2]

[Anonymous], 2017, BAXD DECL PACK INS

[3]

[Anonymous], 2015, FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood

[4]

[Anonymous], 2008, LEV LEV PACK INS

[5]

Barry AL, 2009, J ANTIMICROB CHEMOTH, V64, P1923

[6] Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains [J].

Biedenbach, Douglas J. ;

Turner, Lisa L. ;

Jones, Ronald N. ;

Farrell, David J. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2012, 74 (02) :204-206

[7]

Buissonniere A, 2008, P 48 INT C ANT AG CH

[8]

Cammarata S, 2015, ID WEEK M OCT 7 11 S

[9]

Centers for Disease Control and Prevention, ANT RES

[10]

Centers for Disease Control and Prevention, 2017, ANT RES GON

← 1 2 3 4 →